Journal of Cancer Metastasis and Treatment

Scope & Guideline

Unraveling the complexities of cancer treatment.

Introduction

Immerse yourself in the scholarly insights of Journal of Cancer Metastasis and Treatment with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2394-4722
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationJ CANCER METAS TREAT / J. Cancer Metastasis Treat.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

The Journal of Cancer Metastasis and Treatment is dedicated to advancing the understanding of cancer metastasis and treatment methodologies. The journal aims to publish high-quality research that contributes to the fields of oncology, molecular biology, and therapeutic interventions in cancer care. Below are the core areas of focus:
  1. Cancer Metastasis Mechanisms:
    Exploration of the biological processes and molecular mechanisms that underlie cancer metastasis, including tumor microenvironment interactions and cellular signaling pathways.
  2. Innovative Treatment Strategies:
    Investigation of novel therapeutic approaches, including immunotherapy, targeted therapy, and emerging drug combinations that improve patient outcomes in various cancer types.
  3. Clinical Research and Trials:
    Reporting on clinical studies, trials, and retrospective analyses that provide insights into the efficacy and safety of cancer treatments across diverse patient populations.
  4. Biomarkers and Prognostic Indicators:
    Identification and validation of biomarkers that can predict treatment response, disease progression, and patient prognosis in cancer patients.
  5. Translational Research:
    Focus on bridging laboratory findings with clinical applications to enhance treatment modalities and patient care in oncology.
  6. Multidisciplinary Approaches:
    Encouragement of collaborative research that integrates various disciplines, such as surgery, radiology, and pharmacology, to address complex cancer challenges.
The journal has seen a rise in focus on several trending and emerging themes, reflecting advancements in cancer research and treatment methodologies. These themes represent the forefront of current investigations and clinical applications:
  1. Immunotherapy Innovations:
    There is an increasing volume of research dedicated to immunotherapy, including combination strategies with checkpoint inhibitors, highlighting their potential in various cancer types.
  2. Machine Learning and AI Applications:
    The integration of machine learning and artificial intelligence in analyzing clinical data and omics is gaining traction, showcasing its potential to predict treatment outcomes and personalize therapy.
  3. Microbiome and Cancer Interactions:
    Research exploring the role of the microbiome in cancer treatment responses and disease progression is emerging as a significant area of interest, emphasizing its impact on patient health.
  4. Liquid Biopsy Techniques:
    The development and application of liquid biopsy methods for early cancer detection and monitoring treatment responses are increasingly featured, reflecting a shift towards less invasive diagnostic approaches.
  5. Targeted Therapies and Personalized Medicine:
    A growing emphasis on precision medicine and the identification of molecular targets for tailored treatment strategies is evident, as researchers seek to optimize therapeutic efficacy.
  6. Cancer Stem Cell Research:
    The investigation of cancer stem cells and their role in metastasis and treatment resistance is trending, as understanding these cells is crucial for developing effective therapies.

Declining or Waning

While the Journal of Cancer Metastasis and Treatment continues to explore a wide range of themes, certain areas of focus appear to be waning in prominence. The following themes have seen a decline in recent publications:
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable shift away from discussions centered on traditional chemotherapy, as newer targeted therapies and immunotherapy options gain traction in the field.
  2. Single-Agent Therapy Studies:
    Research focusing solely on the efficacy of single-agent therapies is becoming less common, with a growing emphasis on combination therapies that enhance treatment effectiveness.
  3. Basic Cancer Biology Studies:
    While foundational research remains important, there is a decreasing emphasis on purely basic science studies without direct clinical application, as the journal leans towards translational research.
  4. Historical Treatment Protocols:
    Papers discussing outdated treatment protocols or historical perspectives on cancer management are less frequently published, reflecting a move towards contemporary practices and innovations.

Similar Journals

CANCER INVESTIGATION

Pioneering insights in oncology for a healthier tomorrow.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

NEOPLASMA

Shaping the Future of Cancer Science
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

Cancer Research Communications

Elevating cancer research to new heights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Annual Review of Cancer Biology

Exploring the Complexities of Cancer Science
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

BRITISH JOURNAL OF CANCER

Pioneering Insights in Oncology Since 1947.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

CURRENT CANCER DRUG TARGETS

Innovating drug discovery at the forefront of cancer research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

OncoTargets and Therapy

Empowering breakthroughs in oncology and pharmacology.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6930Frequency: 1 issue/year

OncoTargets and Therapy is a prestigious, peer-reviewed journal dedicated to the rapid dissemination of research in the fields of oncology and pharmacology. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this journal has embraced the open access model, ensuring that critical cancer-related research is freely accessible to a global audience. With an impressive impact factor reflected by its Q2 ranking in both the Oncology and Pharmacology (medical) categories for 2023, as well as Scopus rankings placing it in the top 91st percentile in pharmacology and the 84th percentile in oncology, OncoTargets and Therapy stands out as a vital resource for researchers, clinicians, and students alike. The journal focuses on therapeutics, novel drug discoveries, and clinical trials, encouraging collaborative efforts to combat cancer effectively. By providing a platform for groundbreaking studies and comprehensive reviews, it plays a crucial role in advancing knowledge and practice in these critical areas of medical science.

Molecular Cancer

Transforming cancer knowledge into clinical practice.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

MOLECULAR CARCINOGENESIS

Decoding the Pathways of Cancer Development
Publisher: WILEYISSN: 0899-1987Frequency: 12 issues/year

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

CLINICAL & EXPERIMENTAL METASTASIS

Illuminating Pathways in Cancer Progression
Publisher: SPRINGERISSN: 0262-0898Frequency: 6 issues/year

CLINICAL & EXPERIMENTAL METASTASIS is a highly regarded academic journal dedicated to the study of cancer metastasis, published by Springer. With an ISSN of 0262-0898 and an E-ISSN of 1573-7276, this journal serves as a pivotal resource for researchers and professionals dedicated to understanding the complexities of metastatic disease. Based in the Netherlands, it boasts an impressive impact factor, solidifying its position in two major quartiles: Q2 in Cancer Research and Q1 in both Medicine (Miscellaneous) and Oncology for 2023. The journal not only ranks among the top tier in Medicine Oncology—84th out of 404—but also excels in Biochemistry, Genetics and Molecular Biology in Cancer Research, ranking 75th out of 230. With coverage spanning from 1983 to 2024, CLINICAL & EXPERIMENTAL METASTASIS presents cutting-edge research, reviews, and clinical studies that drive the field forward. This journal is essential for anyone looking to deepen their understanding of cancer metastasis and its underlying mechanisms.